Top Menu

Archive | DTC-In-Perspective by Bob Ehrlich

Bob Ehrlich

DTC in Perspective: Could Amazon Change the Drug Market?

The widely reported story that Amazon is considering entering the prescription drug market has made current drug sellers nervous. Could Amazon revolutionize drug sales? Or, would they just be another mail order supplier in a crowded market? The answer is unclear. Amazon certainly has the strength to cut deals with drug companies, insurers and major […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: Obamacare Stays, Drug Companies at Risk

With the failure to come up with an alternative to Obamacare, Congress has left drug companies in a more precarious position. The goal was to make health care more free market oriented and less government controlled. That would have created more competition among health care providers and insurance companies. Patients would have more choice and […]

Continue Reading 0
Bob Ehrlich

DTC in Perspective: FDA Research Reinforces Warning Rationale

Many recent FDA warning letters involve what they say are distracting visuals during risk discussion. Last year Otezla and Toujeo were cited for that. A recent study using eye tracking reinforced their view that visual backgrounds on TV ads are potentially hurting comprehension of risks. Drug makers frequently mention some of the risks using supers […]

Continue Reading 0